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Aim To identify the risk factors of a repeated episode of se-
vere febrile neutropenia (FN) and to build an accurate and 
easy-to-use predictive model.
Methods This single-center retrospective cohort study 
conducted at the Clinical Hospital Center Children’s Hos-
pital Rijeka from January 1, 2008 to December 31, 2016 
included pediatric patients with malignant diseases who 
experienced at least one FN episode. The association of 
the second severe FN episode appearance with relevant 
clinical and laboratory data was analyzed by logistic regres-
sion.
Results Out of 45 patients with one FN episode, 25 (56%) 
had severe FN and 11 (24%) had repeated severe FNs. Sig-
nificant predictors of a repeated severe FN episode were 
the first FN episode duration of 9 or more days and red 
blood cells ≤3.0 × 1012/L. The predictive model construct-
ed by crossing these two indicators had the accuracy of 
87% (95% confidence interval [CI] 73%-94%), sensitivity 
of 82% (95% CI 53%-97%), and specificity of 88% (95% CI 
79%-93%).
Conclusion The first FN episode duration and anemia are 
significantly associated with the risk for severe FN re-occur-
rence. These factors may be useful in the identification of 
children with cancer who are at high risk for adverse out-
come at any future fever onset and may benefit from early 
intensive treatment. Received: January 17, 2019
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The majority of pediatric malignances are treated by sys-
temic combined chemotherapy, and approximately 80% of 
children are cured. Antineoplastic therapy adversely affects 
myelopoiesis and damages the integrity of gastrointestinal 
mucous membrane, leading to the invasion of colonizing 
bacteria and the development of a dangerous, quickly pro-
gressing systemic infection (1). Febrile neutropenia (FN) is 
the leading cause of immediate hospitalization in children 
with cancer and the most frequent complication of che-
motherapy. It increases the morbidity and mortality due to 
serious infections (2-7).
In children with cancer, the beginning phase of a system-
ic bacterial infection, requiring early antibiotics treatment, 
has to be immediately differentiated from viral respirato-
ry infections (8). However, the routine laboratory tests are 
not sensitive and specific enough for early detection of 
systemic inflammation. Some of these tests are also often 
time-consuming, such as blood cultures and antimicro-
bial susceptibility testing, which is still the gold standard 
for diagnostics and targeted therapy in systemic infec-
tions (9,10). Systems of prediction known as clinical deci-
sion rules (CDRs), on the other hand, do not include pa-
tient’s individual characteristics into risk calculation and 
have not undergone external validation necessary for a 
wider clinical use (3,8). Monthly cycling antibiotic therapy 
emerged as a potential solution, but it needs to be further 
researched (11,12). The predictive value of serum concen-
trations of interleukin (IL)-6, IL-8, IL-10, and procalcitonin 
has also been analyzed, but the problem of early risk strat-
ification has not been resolved (13-15). Data on predic-
tive value of hemoglobin concentrations or red blood cell 
(RBC) count, known as indicators of myelosuppression, are 
similarly conflicting (16).
The overall outcome in children with malignant diseases 
can be improved by the reliable identification of individu-
als at high risk of systemic infections development at the 
time of fever onset (8,9,17). The International Consensus 
Statement for Core Outcomes and Definitions for Pediatric 
Fever and Neutropenia was agreed upon in 2015 to further 
develop this field but there are still no clear treatment al-
gorithms (18). As the previously tested predictive models 
for any FN episode in children with cancer did not show 
clear clinical usefulness, we hypothesize that the focus 
should be on the prediction of repeated FN, and especially 
on repeated severe FN. Our aim was to determine which of 
the first FN episode clinical features could predict severe 
FN re-occurrence and facilitate clinical decision-making on 
early intensive antibiotic therapy in the next fever onset.
MAteRiAlS AnD MethoDS
Patients and study design
This retrospective single-center cohort study was conduct-
ed at the Clinical Hospital Center Rijeka, Location Kantrida, 
Department of Hematology and Oncology, Clinical Hos-
pital Center Children’s Hospital Rijeka, Croatia. Data were 
collected from the hospital electronic records for patients 
treated from January 1, 2008 to December 31, 2016.
The inclusion criterion was the first episode of FN, while 
the exclusion criterion were incomplete data in medical 
history. We analyzed the medical records of 225 children 
with malignant diseases, while the final sample included 
45 (20%) children who experienced at least one FN epi-
sode. Zero time was the time point of the beginning of the 
first FN episode.
The key outcome was a repeated episode of severe FN. 
The criteria for severe FN diagnosis were the absolute neu-
trophil count (ANC)≤500/mm3, the temperature ≥38.5°C 
(≥101.30°F), and duration longer than two days. Observed 
predictors were from three large groups of data: social, de-
mographic and vitality, laboratory, and clinical data (18-21). 
The study protocol was approved by the Clinical Hospital 
Center Rijeka Ethics Committee and the University of Rijeka 
School of Medicine Ethics Committee (No 19-03-0-013).
Statistical analysis
Normality of data distribution was tested with the Kolmog-
orov-Smirnoff test. Data are presented as median and in-
terquartile ranges. The predictive model was constructed 
in three steps. In the first step, the association of all vari-
ables with a severe FN repeated episode was assessed by 
univariate/unadjusted binary logistic regression. The vari-
ables that were significantly associated (P < 0.05) were in-
cluded into the second step, when their association with 
severe FN repeated episode was analyzed by multivariate 
adjusted binary logistic regression. In the third step, two 
variables that showed significant partial/adjusted associa-
tion with the criterion were combined into the final model. 
In predictive value analysis of the new model we calculat-
ed the overall accuracy, sensitivity, specificity, positive and 
negative likelihood ratios, and predictive values. The level 
of statistical significance was set to P < 0.05, and all con-
fidence intervals were given on this level. The analyses 
were carried out using SPSS 17.0 (SPSS Inc., Chicago, 
IL, USA). Confidence intervals for proportions were 
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determined using Statistics Calculator 3.0 (Stat Pac Inc., 
Bloomington, MN, USA). Measures of predictive value were 
calculated by John C. Pezzullo online calculator (http://
statpages.org/ctab2x2.html).
ReSultS
Thirty-eight of 45 patients (84%) experienced a repeated 
FN, and the median number of FN episodes was 2 (range, 
1-5). Twenty-five patients (55%) experienced severe FN and 
11 (24%) experienced a second severe episode (Table 1).
In the first step of the univariate unadjusted binary logis-
tic regression, six parameters were significantly associated 
with the severe repeated FN episode: lowest ANC≤300/
mm3; duration of the first episode of 9 or more days; bone 
marrow suppression; RBC≤3.0 × 1012; hematocrit ≤0.25 
(25%); and platelets ≤100 × 109 (Table 2).
Two final significant predictors in the multiple regression 
were duration of the first episode of 9 or more days and 
RBC≤3.0 × 1012 (Table 2). These two variables combined 
accounted for approximately Nagelkerke R2 = 58% of the 
repeated severe FN episode variance. The final, simplified 
predictive model was constructed by crossing these two 
indicators (Table 3). High risk of severe FN repeated epi-
sode was indicated either by duration of the first episode 
of 9 or more days or by RBC≤3.0 × 1012, while low risk was 
indicated by the opposite values: duration of the first epi-
sode ≤8 days and RBC>3.0 × 1012. The new constructed 
predictor was significantly associated with the severity of 
repeated FN episode (Fisher exact test, P < 0.001) (Table 
3). The overall accuracy of the model was 87% (95% CI 
73%-94%), with the sensitivity of 82% (53%-97%) and the 
specificity of 88% (79%-93%). Positive likelihood ratio for 
repeated FN episode was 7.0 (95% CI 2.52-13.73). Negative 
likelihood ratio was 0.21 (95% CI 0.04-0.56).
DiSCuSSion
This study showed two predictors of the re-occurrence of 
repeated severe FN: duration of the first FN episode of 9 or 
more days and RBC≤3.0 × 1012. Our model based on two 
predictors showed very good specificity, sensitivity, and 
negative predictive value and could be useful in clinical 
practice. To the best of our knowledge, these factors have 
not previously been shown to be significant predictors for 
severe FN. The duration of the first episode of 9 or more 
days could indicate slower hematopoietic recovery, while 
the lower RBC count can be a consequence of myelosup-
pression or bone marrow infiltration. As the pathophysiol-
ogy of FN is multifactorial, other possible causes have also 
to be taken into consideration (15).
Considerable evidence has been published on different 
single and combined predictors for severe FN. C reactive 
protein ≥90 mg/L, hypotension, platelet number ≤50 000 
/mm3, relapsed leukemia, and chemotherapy in the last 
7 days were shown to be the predictors for severe bacte-
rial infection (19), while intensive chemotherapy, shorter 
time-to-diagnosis, presence of CVC and previous FN were 
shown to be predictors for development of FN and FN with 
bacteremia (20).
Our study found several significant univariate predictors. 
ANC≤300/mm3 was a good predictor of severe FN epi-
tABle 1. Patients’ characteristics (n = 45)*
Sociodemographic and 
vital parameters n (%) or median (25-75)
Sex
male  25 (55.6)
female  20 (44.4)
Age at the diagnosis, years   5.0 (5.0-13.0)
BMi at first Fn episode  16.0 (14.5-18.0)
type of malignant disease
acute lymphoblastic leukemia  17 (37.8)
neuroblastoma   5 (11.1)
non-Hodgkin’s lymphoma   5 (11.1)
other diagnosis†  18 (40.0)
Solid tumor  26 (57.8)
Metastatic disease   7 (15.6)
Bone marrow involvement  15 (33.3)
Broviac catheter  29 (64.4)
Duration of hospitalization in days  43 (23-77)
Febrile neutropenia (Fn)
at least one repeated episode  38 (84.4)
average number of episodes   2 (1-5)
severe FN  25 (55)
Repeated Fn episode
ANC 282 (17-500)
ANC≤500/mm3  27 (60.0)
temperature in °C  39.4 (38.8-39.8)
duration in days   2.5 (2.0-4.5)
duration ≥3 days  19 (42.2)
severe second FN episode  11 (24.4)
*Fn – febrile neutropenia; AnC – absolute neutrophil count.
†other diagnosis, two patients each: acute myeloid leukemia, ag-
gressive fibromatosis, ewing’s sarcoma, hepatoblastoma, hodgkin 
lymphoma, medulloblastoma, Yolk sac tumor. other diagnosis, one 
patient each: ganglioneuroblastoma, nephroblastoma, osteosarcoma, 
rhabdomyosarcoma.
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sodes, which is consistent with the results by Ammann 
et al (15). Also, hematocrit ≤0.25 was a good predictor, 
pointing toward bone marrow suppression or bone mar-
row infiltration as a possible explanation for FN suscepti-
bility. Bone marrow involvement in malignant disease was 
also univariately significant, while in other studies it dem-
onstrated multivariate significance (15,20). Platelet count 
≤100 × 109/L was a good univariate predictor in our study, 
as well as in other studies (20), even in multivariate models 
(19,22). Other parameters investigated in this study were 
found to be non-significant by other authors (19,22).
Disease-specific factors depending on the type of malig-
nant disease, type and dose of chemotherapy, comorbidi-
ties, early complications, and other patients’ characteristics 
make the risk assessment by general score systems prob-
lematic (23-25). Only one of the available CDRs is method-
ologically suitable, however, it was developed and validat-
ed in South America, making its application in other parts 
of the world questionable (26). Also, while the greatest part 
of CDRs identify children at low risk of severe infection, only 
one of them aims at diagnosing severe bacterial infection 
(26-29). Better risk-stratification of patients based on our 
model could lead to a less intensive treatment in low-risk 
patients, which carries a lower risk of side effects and hos-
pital acquired infections, lower toxicity risk and the risk of 
antibiotic resistance development, better quality of life for 
the child and the family, as well as lower costs. However, 
identifying children at low risk cannot have the advantage 
over the identifying children at high risk who can be suc-
cessfully cured by an early intensive antimicrobial therapy.
Our proposal is oriented toward the general risk as-
sessment and includes both of these groups. Also, 
tABle 2. Predictors associated (P < 0.05) with repeated episode of severe febrile neutropenia (Fn) (n = 45)
Severe Fn repeated episode
n (%) yes no total oRuni (95% Ci) oRmulti (95% Ci)
lowest AnC at first Fn episode
ANC≤300/mm3 10 (38.5) 16 (61.5) 26 (100) 11.3 (1.21-261.6)   4.3 (0.26-71.59)
ANC>300/mm3  1 (5.3) 18 (94.7) 19 (100)
Duration of the first Fn episode
≥9 days  6 (66.7)  3 (33.3)  9 (100) 12.4 (2.32-66.35)  30.4 (1.94-476.49)
≤8 days  5 (13.9) 31 (86.1) 36 (100)
Bone marrow involvement
yes  7 (46.7)  8 (53.3) 15 (100)  5.7 (1.32-24.54)   1.5 (0.16-13.69)
no  4 (13.3) 26 (86.7) 30 (100)
Red blood cells
≤3.0 × 1012  4 (80.0)  1 (20.0)  5 (100) 18.3 (1.76-189.63) 130.6 (1.3-13011)
>3.0 × 1012  7 (17.9) 32 (82.1) 39 (100)
hematocrit
≤0.25  5 (71.4)  2 (28.6)  7 (100) 13.3 (2.08-85.41)   0.3 (0.00-9.77)
>0.25  6 (15.8) 32 (84.2) 38 (100)
Platelets
≤100 × 109  5 (50.0)  5 (50.0) 10 (100)  4.8 (1.06-22.09)   1.0 (0.08-12.73)
>100 × 109  6 (17.1) 29 (82.9) 35 (100)
*oRuni – univariate odds ratio for severe Fn; oRadj – multivariate, binary logistic regression adjusted odds ratio for severe Fn; 95% Ci – 95% confidence 
interval of odds ratio.
tABle 3. Predictive validity for a repeated episode of febrile neutropenia (Fn) (n = 45)
Repeated episode of Fn
estimated risk yes no total
High* 9 (69.2)  4 (30.8) 13 (100) positive predictive value 69% (45%-82%)†
Low 2 (6.3) 30 (93.8) 32 (100) negative predictive value 94% (94%-99%)†
sensitivity 82% (53%-97%)† specificity 88% (79%-93%)†
*high risk of Fn repeated episode was indicated either by duration of the first episode ≥9 days or by RBC≤3.0 × 1012.  
†Values in parentheses represent 95% confidence intervals.
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our results seem to be more appropriate for severe FN 
prediction in pediatric oncologic patients than the Sys-
temic Inflammatory Response Syndrome (30), which is 
used for sepsis diagnosis but is generally questionable 
in oncologic patients, since it was based on studies that 
did not include a considerable number of patients with 
tumors and neutropenia. MASCC risk score by the Asso-
ciation for Supportive Care in Cancer, which assesses the 
risk of adverse outcome in oncologic patients, is also not 
suitable for children with tumors, since it shows gaps in 
evidence and requires numerous tests to be made (CRP, 
procalcitonin, venous blood lactate, proteinemia and 
phosphatemia evaluation, blood lactate, antithrombin, 
and VIIa factor levels, and chest x-ray) (31).
The results of this study need to be validated on larger pa-
tient populations. Also, the number of our patients did not 
allow sub-analyses according to malignant disease type, 
phase, chemotherapy type, and chemotherapy intensity. 
Long time period in which the study was conducted could 
have influenced the final results, and data on the time-to-
antibiotic administration were not available.
In conclusion, we propose a predictive model for the sec-
ond FN episode based on a new combination of two eas-
ily accessible risk factors. This model could be used for risk 
assessment in different malignant diseases, chemotherapy 
types, and chemotherapy intensities. Our approach might 
represent a step toward an individually tailored FN therapy 
and the prediction of repeated severe FN episode in pedi-
atric oncology, facilitating decision-making on inpatient vs 
outpatient management.
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